



Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507

Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com

October 30, 2021

To,
The Secretary/Executive Director
BSE Limited
National Stock Exchange of India Limited
New York Stock Exchange, Inc.
NSE-IFSC Limited

Dear Sir/Madam,

Sub: Newspaper advertisement regarding financial results for the quarter and half-year ended September 30, 2021

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, please find enclosed copies of newspaper advertisement regarding the financial results of the company for the quarter and half-year ended September 30, 2021 as published in Business Standard and Andhra Prabha on October 30, 2021.

This is for your information and records.

With regards,

Sandeep Poddar
Company Secretary

Encl: as above

సంస్థ, విజ్ఞాన మం
సంస్థించి ఉత్పత్తి
రానున్న
గణనీయమైన
తీర్చడంలో
త: డైరెక్టర్
తీర్చడంలో
నిత్యసంస్థానా
సంప్రదించు
వ్యక్తి అవసరాలు
లార్ విద్యుత్
వేగము న్నారు.
లోనూ మరిన్ని
రని, మైనింగ్ రం
అవకాశాలు న్నా
వ్యాసంస్థలకు
అసోషియేషన్
వ్యక్తం చేశారు.

No.	Particulars	30.09.2021	30.09.2020	30.09.2021	30.09.2020
1	Total Income	25,813.41	24,199.87	46,107.67	44,811.99
2	Net profit for the period before tax	2,757.81	2,868.56	3,965.13	4,899.58
3	Net profit for the period after tax	2,037.11	2,144.00	2,910.56	3,660.30
4	Total comprehensive income for the period	1,662.76	2,118.43	2,534.67	3,639.59
5	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	1,290.05	1,290.05
6	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)				
	(a) Basic	15.88	16.71	22.69	28.53
	(b) Diluted	15.88	16.71	22.69	28.53

Note 1: The financial results for the quarter and half year ended 30 September 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 29 October 2021.

Note 2: Key Standalone Financial Information: (Amount in lakhs of ₹)


Particulars	Quarter Ended 30.09.2021	Quarter Ended 30.09.2020	Half Year Ended 30.09.2021	Half Year Ended 30.09.2020
Total Income	25,813.41	24,199.85	46,107.67	44,811.97
Net profit for the period before tax	2,753.39	2,858.40	3,952.00	4,878.80
Net profit for the period after tax	2,032.69	2,133.84	2,897.45	3,639.52

Note 3: The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.neulandlabs.com

By Order of the Board
For and on behalf of the Board of Directors

Dr. D.R.Rao
Executive Chairman
(DIN 00107737)

Place: Hyderabad
Date : 29 October 2021


Dr.Reddy's

Extract of unaudited financial results of Dr. Reddy's Laboratories Limited and its subsidiaries for the quarter and half year ended 30 September 2021 prepared in compliance with Indian Accounting Standards

All amounts in Indian Rupees millions

Sl. No.	Particulars	Consolidated		
		Quarter ended 30.09.2021 (Unaudited)	Half year ended 30.09.2021 (Unaudited)	Quarter ended 30.09.2020 (Unaudited)
1	Total Revenue from operations	57,869	107,320	49,109
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	12,725	18,283	8,729
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	12,725	18,283	8,729
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	9,958	13,762	7,718
5	Total Comprehensive Income for the period	9,643	12,602	7,812
6	Equity Share Capital	832	832	831
7	Reserves (excluding Revaluation Reserve)	184,612	184,612	165,843
8	Earnings per share (in Rupees) per Rs. 5/- share			
	Basic	60.03	82.99	46.54
	Diluted	59.88	82.77	46.40

Sl. No.	Particulars	Standalone		
		Quarter ended 30.09.2021 (Unaudited)	Half year ended 30.09.2021 (Unaudited)	Quarter ended 30.09.2020 (Unaudited)
1	Total Revenue from operations	38,234	72,569	33,458
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	6,487	11,932	6,197
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	6,487	11,932	6,197
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	4,490	8,624	4,810
5	Total Comprehensive Income for the period	4,625	8,415	5,073
6	Equity Share Capital	832	832	831
7	Reserves (excluding Revaluation Reserve)	173,843	173,843	162,037
8	Earnings per share (in Rupees) per Rs. 5/- share			
	Basic	27.07	52.01	29.00
	Diluted	27.00	51.87	28.92

Notes:

- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchanges website: www.bseindia.com and www.nseindia.com and also on the Company's website: www.drreddys.com.
- The unaudited results have been reviewed by the Audit Committee of the Board at their meeting held on 28 October 2021 and approved by the Board of Directors of the Company at their meeting held on 29 October 2021.

By order of the Board
For Dr. Reddy's Laboratories Limited

G V Prasad
Co-Chairman & Managing Director

Place : Hyderabad
Date : 29 October 2021

Dr. REDDY'S LABORATORIES LIMITED
Regd. Office: 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034, Telangana, India
CIN: L85195TG1984PLC004507, Tel: 91 40 4900 2900, Fax: 91 40 4900 2999
email: shares@drreddys.com, website: www.drreddys.com

Notes

- 1) The above is an extract of the detailed format of Quarterly Financial Results of the Company for the quarter and half year ended September 30, 2021 filed with the Stock Exchange under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial results are available on the websites of BSE Limited and the Company at www.avanse.com
- 2) For the other line items referred in Regulation 52 (4) of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, the pertinent disclosures have been made to BSE Limited and can be accessed on www.bseindia.com
- 3) Networth is equal to paid up equity share capital plus other equity less deferred tax assets less intangible assets less right of use asset and corresponding liabilities
- 4) Capital Redemption Reserve, Debenture Redemption Reserve, Debt Service Coverage Ratio and Interest Service Coverage Ratio are not applicable as per Regulation 52 (4) of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015.
- 5) Previous period/year figures have been regrouped / reclassified wherever necessary to correspond with the current year classification/disclosure.

For Avanse Financial Services Ltd


Vijayalakshmi Iyer

Chairperson

(DIN 05242960)

Place: Mumbai

Date: October 28, 2021



Extract of unaudited financial results of Dr. Reddy's Laboratories Limited and its subsidiaries for the quarter and half year ended 30 September 2021 prepared in compliance with Indian Accounting Standards

All amounts in Indian Rupees millions

Sl. No.	Particulars	Consolidated		
		Quarter ended 30.09.2021 (Unaudited)	Half year ended 30.09.2021 (Unaudited)	Quarter ended 30.09.2020 (Unaudited)
1	Total Revenue from operations	57,869	107,320	49,109
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	12,725	18,283	8,729
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	12,725	18,283	8,729
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	9,958	13,762	7,718
5	Total Comprehensive Income for the period	9,643	12,602	7,812
6	Equity Share Capital	832	832	831
7	Reserves (excluding Revaluation Reserve)	184,612	184,612	165,843
8	Earnings per share (in Rupees) per Rs. 5/- share			
	Basic	60.03	82.99	46.54
	Diluted	59.88	82.77	46.40

Sl. No.	Particulars	Standalone		
		Quarter ended 30.09.2021 (Unaudited)	Half year ended 30.09.2021 (Unaudited)	Quarter ended 30.09.2020 (Unaudited)
1	Total Revenue from operations	38,234	72,569	33,458
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	6,487	11,932	6,197
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	6,487	11,932	6,197
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	4,490	8,624	4,810
5	Total Comprehensive Income for the period	4,625	8,415	5,073
6	Equity Share Capital	832	832	831
7	Reserves (excluding Revaluation Reserve)	173,843	173,843	162,037
8	Earnings per share (in Rupees) per Rs. 5/- share			
	Basic	27.07	52.01	29.00
	Diluted	27.00	51.87	28.92

Notes:

- 1 The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchanges website: www.bseindia.com and www.nseindia.com and also on the Company's website: www.drreddys.com.
- 2 The unaudited results have been reviewed by the Audit Committee of the Board at their meeting held on 28 October 2021 and approved by the Board of Directors of the Company at their meeting held on 29 October 2021.

By order of the Board
For Dr. Reddy's Laboratories Limited

Place : Hyderabad
Date : 29 October 2021

G V Prasad
Co-Chairman & Managing Director

Dr. REDDY'S LABORATORIES LIMITED

Regd. Office: 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034, Telangana, India
CIN: L85195TG1984PLC004507, Tel: 91 40 4900 2900, Fax: 91 40 4900 2999
email: shares@drreddys.com, website: www.drreddys.com

Business Standard – October 30, 2021